ARCHIVES

First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors

This article is from The Cancer Letter archive.

Vol. 34 No. 6 | June 24, 2011

Download PDF Visit The Full Archive

Related Articles

NIH Seeking More Women, Minorities On Committees

November 9, 1979

ImClone: Waksals To Pay $5 Million To Settle With SEC.

January 28, 2005

Cooperative Group chairmen Cool, But High Priority Trials To Continue

January 18, 1991

In Brief: Holleb To Retire In June As ACS Vice President; Consensus Conference On Neurofibromatosis Set

January 23, 1987

DCT Advisors Approve $22 Mil. Set Aside For Interactive R01s Systemic Therapies

July 10, 1992

Immune System Booster Shown Safe For Prostate Cancer; Fewer Side Effects

August 29, 2008